What is the current Chromosomal Microarray (CMA) Familial Testing market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the CMA Familial Testing market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the CMA Familial Testing market?

Key drivers include increasing genetic disorder prevalence and advancements in technology.

What challenges does the CMA Familial Testing market face?

Challenges include high testing costs and limited awareness in developing regions.

Which regions are leaders in the CMA Familial Testing market?

North America and Europe are current regional leaders due to high healthcare expenditure.

Who are the top companies in the CMA Familial Testing market?

Top companies include Illumina, Thermo Fisher, and Agilent Technologies.

What future opportunities exist in the CMA Familial Testing market?

Future opportunities include increasing demand for non-invasive prenatal testing.

How will technology impact the CMA Familial Testing market?

Advances in microarray technology will improve test accuracy and efficiency.

What is the regulatory landscape for the CMA Familial Testing market?

Regulatory frameworks vary by region, with FDA and CE marking key in the US and EU.

What is the future outlook for the CMA Familial Testing market?

The future outlook is positive, driven by growing demand for genetic testing.

Chromosomal Microarray (CMA) Familial Testing Growth Analysis & Future Outlook 2033

Chromosomal Microarray (CMA) Familial Testing by Application (Medical, Laboratory, Clinical, Others), by Types (Single Nucleotide Polymorphism (SNP), Comparative Genomic Hybridization (CGH)), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Chromosomal Microarray (CMA) Familial Testing Market Overview

The Chromosomal Microarray (CMA) Familial Testing market refers to the genetic testing industry that focuses on identifying chromosomal abnormalities in families. As the global genetic testing market continues to evolve, the CMA Familial Testing market size is expected to reach $1.4 billion by 2026, with a growth outlook that is largely driven by the increasing adoption of genetic testing in prenatal diagnosis, pediatric care, and reproductive health. The market forecast suggests a compound annual growth rate (CAGR) of 10.2% during the forecast period, driven by macro drivers such as advances in genomic technologies, increasing awareness of genetic disorders, and expanding insurance coverage.

Loading chart…

Key forces shaping the CMA Familial Testing industry include technology shifts towards non-invasive prenatal testing, regulatory frameworks that support the use of genetic testing in clinical practice, and changing consumer behavior driven by increasing awareness of genetic health. The largest region for CMA Familial Testing is North America, while the fastest-growing region is Asia-Pacific, driven by expanding healthcare infrastructure and increasing demand for genetic testing services. As the market continues to evolve, industry players must navigate these key forces to capitalize on emerging opportunities and drive market expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Baylor Genetics; MedGenome Labs; Centogene; GeneDx; Quest Diagnostics; LabCorp; Lineagen; Invitae; Illumina Inc.; CD Genomics; Thermo Fisher; Agilent
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Chromosomal Microarray (CMA) Familial Testing market is poised for significant growth, driven by increasing demand for genetic testing and advances in technology. The market dynamics are shaped by various factors, including growth drivers, restraints, opportunities, and challenges.

Growth Drivers2 items

Advances in Chromosomal Microarray (CMA) Familial Testing technology, such as high-resolution arrays and next-generation sequencing, are driving the market forward by enabling faster and more accurate testing.

The growing awareness of genetic disorders and the importance of early diagnosis and treatment are contributing to the increasing Chromosomal Microarray (CMA) Familial Testing market size and growth forecast.

Restraints2 items

The high cost of Chromosomal Microarray (CMA) Familial Testing and the lack of reimbursement in some regions are limiting the market growth, making it inaccessible to a significant portion of the population.

The complexity of interpreting test results and the need for specialized expertise are also hindering the adoption of Chromosomal Microarray (CMA) Familial Testing in some areas.

Opportunities2 items

The increasing demand for non-invasive prenatal testing (NIPT) and the growing importance of genetic testing in _personalized medicine_ are creating new opportunities for the Chromosomal Microarray (CMA) Familial Testing market.

The expansion of Chromosomal Microarray (CMA) Familial Testing into emerging markets, such as Asia-Pacific and Latin America, is expected to drive market growth and increase the Chromosomal Microarray (CMA) Familial Testing market size.

Challenges2 items

The Chromosomal Microarray (CMA) Familial Testing market faces challenges related to regulatory frameworks, as the lack of standardization and inconsistent regulations across regions can hinder market growth and growth forecast.

The need for ongoing education and training of healthcare professionals to ensure the effective use and interpretation of Chromosomal Microarray (CMA) Familial Testing results is a significant challenge that must be addressed.

Market Segmentation

Loading chart…

The Application segment of the Chromosomal Microarray (CMA) Familial Testing market refers to the various uses of CMA testing in familial settings. This includes prenatal testing, postnatal testing, and carrier testing, which contribute to the overall market size. The application segment is a crucial aspect of the Chromosomal Microarray (CMA) Familial Testing segmentation, as it helps identify the primary uses of CMA testing and their corresponding market shares.

The Types segment of the Chromosomal Microarray (CMA) Familial Testing market encompasses various subtypes, including [object Object] and [object Object]. This segment is vital in understanding the market taxonomy, as it categorizes the different types of CMA tests used in familial settings. By analyzing the types segment, researchers can determine the market share of each subtype and identify trends in the Chromosomal Microarray (CMA) Familial Testing market.

Chromosomal Microarray (CMA) Familial Testing Segmentation Breakdown8 items

Application

Medical

Laboratory

Clinical

Others

Types

Single Nucleotide Polymorphism (SNP)

Comparative Genomic Hybridization (CGH)

Regional Insights

Loading chart…

The Chromosomal Microarray (CMA) Familial Testing market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of genetic testing, favorable policies, and significant investments in healthcare infrastructure. Key drivers for North America include high ecosystem maturity, a large patient population, and advanced infrastructure.

In Europe, key drivers include rising demographics with a growing elderly population, increasing awareness about genetic disorders, and a well-established healthcare system. Asia Pacific's growth is further fueled by a large and growing middle-class population, increasing access to healthcare services, and a rising demand for genetic testing. Latin America and Middle East & Africa are expected to experience slower growth due to limited infrastructure and lower adoption rates, but are still expected to contribute to the overall regional forecast.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by emerging economies such as China and India. Meanwhile, North America and Europe will continue to dominate the market, driven by their established healthcare ecosystems and high adoption rates of Chromosomal Microarray (CMA) Familial Testing. Latin America and Middle East & Africa will experience steady growth, driven by increasing investments in healthcare infrastructure and rising demand for genetic testing.

Competitive Landscape

The Chromosomal Microarray (CMA) Familial Testing market exhibits a moderately consolidated structure, with a mix of global players and local companies competing for market share. The Chromosomal Microarray (CMA) Familial Testing competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to have an advantage in terms of economies of scale and brand recognition, while local companies focus on regional expertise and customized services.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, and commoditization, which can erode their competitive edge. To stay ahead, companies must continually innovate and adapt to changing market conditions.

Baylor Genetics: regional expansion

MedGenome Labs: innovation pipeline

Centogene: premium pricing

GeneDx: vertical integration

Quest Diagnostics: OEM tie-ups

LabCorp: local manufacturing

Key Chromosomal Microarray (CMA) Familial Testing Companies12 items

Baylor Genetics

MedGenome Labs

Centogene

GeneDx

Quest Diagnostics

LabCorp

Lineagen

Invitae

Illumina Inc.

CD Genomics

Thermo Fisher

Agilent

Market Ecosystem

The Chromosomal Microarray (CMA) Familial Testing ecosystem encompasses a complex network of participants, from technology providers and suppliers to end users. This ecosystem can be broadly segmented into upstream, midstream, and downstream components, with value created and captured at each stage. Technology providers and suppliers form the upstream segment, while integrators and channels constitute the midstream. The downstream segment comprises end users, who ultimately drive demand for CMA Familial Testing services.

Raw material/component suppliers — providing genetic testing materials

Technology providers — developing CMA testing platforms

System integrators / EPCs — integrating CMA testing systems

Distributors / channel partners — supplying CMA testing kits

Service providers / after-sales — offering CMA testing services

End users / buyers — undergoing CMA familial testing

Regulators/standards bodies — establishing CMA testing standards

In the Chromosomal Microarray (CMA) Familial Testing ecosystem, control points are primarily held by regulators and standards bodies, who influence adoption through approvals and standards. Dependency risks arise from input constraints, such as the availability of genetic testing materials, and standards, which can vary by region. Switching costs and partnerships are also significant, as end users may face difficulties in transitioning between different CMA testing platforms. Furthermore, interoperability requirements can pose challenges, particularly in regions with diverse regulatory frameworks, highlighting the need for a comprehensive value chain analysis to navigate the CMA Familial Testing ecosystem effectively.

Recent Industry Insights

The Chromosomal Microarray (CMA) Familial Testing industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between genetic testing companies and research institutions, have driven innovation in the field. Notable mergers and acquisitions have also taken place, leading to increased consolidation and expanded service offerings in the market.

Furthermore, the launch of advanced product and technology solutions has improved the accuracy and efficiency of CMA familial testing. Regulatory changes, including updated guidelines for genetic testing, have also impacted the industry. A shift in consumer and enterprise trends towards personalized medicine has driven demand for CMA familial testing, with companies responding through funding rounds and expansions to meet this growing need.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Chromosomal Microarray (CMA) Familial Testing market outlook. The market attractiveness is moderate, driven by increasing awareness of genetic disorders and advancements in testing technologies. Competitive intensity is high, with key players investing in research and development to improve testing accuracy and efficiency. The long-term outlook is positive, with growing demand for familial testing and expanding applications in personalized medicine.

The innovation landscape is rapidly evolving, with emerging technologies such as next-generation sequencing enhancing the Chromosomal Microarray (CMA) Familial Testing market. Demand-supply balance is expected to be stable, with increasing demand met by expanding capacity from existing and new market entrants. Key risk factors include regulatory changes, reimbursement policies, and public awareness of genetic testing. Overall, the market presents opportunities for growth and investment, driven by the increasing importance of genetic testing in family planning and disease prevention.

11 items

1. Executive Summary

2. Chromosomal Microarray (CMA) Familial Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Chromosomal Microarray (CMA) Familial Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Chromosomal Microarray (CMA) Familial Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Medical

6.1.2. Laboratory

6.1.3. Clinical

6.1.4. Others

6.2. Global Chromosomal Microarray (CMA) Familial Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Single Nucleotide Polymorphism (SNP)

6.2.2. Comparative Genomic Hybridization (CGH)

6.3. Global Chromosomal Microarray (CMA) Familial Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Chromosomal Microarray (CMA) Familial Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Chromosomal Microarray (CMA) Familial Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Chromosomal Microarray (CMA) Familial Testing Market Competition by Key Manufacturers

8.1. Global Chromosomal Microarray (CMA) Familial Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Chromosomal Microarray (CMA) Familial Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Baylor Genetics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. MedGenome Labs

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Centogene

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GeneDx

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Quest Diagnostics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. LabCorp

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Lineagen

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Invitae

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Illumina Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. CD Genomics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Thermo Fisher

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Agilent

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Chromosomal Microarray (CMA) Familial Testing Market

Figure 4: Global Chromosomal Microarray (CMA) Familial Testing Market: Drivers

Figure 5: Global Chromosomal Microarray (CMA) Familial Testing Market: Challenges

Figure 6: Global Chromosomal Microarray (CMA) Familial Testing Market: Trends

Figure 7: Global Chromosomal Microarray (CMA) Familial Testing Market: Opportunity

Figure 8: Global Chromosomal Microarray (CMA) Familial Testing Market: Restraint

Figure 9: Global Chromosomal Microarray (CMA) Familial Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Chromosomal Microarray (CMA) Familial Testing Market Value (USD Million) By Region

Figure 15: Global Chromosomal Microarray (CMA) Familial Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Chromosomal Microarray (CMA) Familial Testing Market Value (USD Million) By Region

Figure 23: Global Chromosomal Microarray (CMA) Familial Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Chromosomal Microarray (CMA) Familial Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Chromosomal Microarray (CMA) Familial Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Chromosomal Microarray (CMA) Familial Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Chromosomal Microarray (CMA) Familial Testing Market Value (USD Million) By Region

Table 10: Global Chromosomal Microarray (CMA) Familial Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Chromosomal Microarray (CMA) Familial Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Chromosomal Microarray (CMA) Familial Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Chromosomal Microarray (CMA) Familial Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Baylor Genetics Basic Information And Sales Area

Table 31: Baylor Genetics. Products Portfolio

Table 32: MedGenome Labs Basic Information And Sales Area

Table 33: MedGenome Labs. Products Portfolio

Table 34: Centogene Basic Information And Sales Area

Table 35: Centogene. Products Portfolio

Table 36: GeneDx Basic Information And Sales Area

Table 37: GeneDx. Products Portfolio

Table 38: Quest Diagnostics Basic Information And Sales Area

Table 39: Quest Diagnostics. Products Portfolio

Table 40: LabCorp Basic Information And Sales Area

Table 41: LabCorp. Products Portfolio

Table 42: Lineagen Basic Information And Sales Area

Table 43: Lineagen. Products Portfolio

Table 44: Invitae Basic Information And Sales Area

Table 45: Invitae. Products Portfolio

Table 46: Illumina Inc. Basic Information And Sales Area

Table 47: Illumina Inc.. Products Portfolio

Table 48: CD Genomics Basic Information And Sales Area

Table 49: CD Genomics. Products Portfolio

Table 50: Thermo Fisher Basic Information And Sales Area

Table 51: Thermo Fisher. Products Portfolio

Table 52: Agilent Basic Information And Sales Area

Table 53: Agilent. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Chromosomal Microarray (CMA) Familial Testing Market Value (USD Million) By Region

Table 59: Global Chromosomal Microarray (CMA) Familial Testing Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Chromosomal Microarray (CMA) Familial Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Baylor Genetics; MedGenome Labs; Centogene; GeneDx; Quest Diagnostics; LabCorp; Lineagen; Invitae; Illumina Inc.; CD Genomics; Thermo Fisher; Agilent
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

The complexity of interpreting test results and the need for specialized expertise are also hindering the adoption of Chromosomal Microarray (CMA) Familial Testing in some areas.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Chromosomal Microarray (CMA) Familial Testing Segmentation Breakdown8 items

Application

Medical

Laboratory

Clinical

Others

Types

Single Nucleotide Polymorphism (SNP)

Comparative Genomic Hybridization (CGH)

Regional Insights

Loading chart…

Competitive Landscape

Baylor Genetics: regional expansion

MedGenome Labs: innovation pipeline

Centogene: premium pricing

GeneDx: vertical integration

Quest Diagnostics: OEM tie-ups

LabCorp: local manufacturing

Key Chromosomal Microarray (CMA) Familial Testing Companies12 items

Baylor Genetics

MedGenome Labs

Centogene

GeneDx

Quest Diagnostics

LabCorp

Lineagen

Invitae

Illumina Inc.

CD Genomics

Thermo Fisher

Agilent

Market Ecosystem

Raw material/component suppliers — providing genetic testing materials

Technology providers — developing CMA testing platforms

System integrators / EPCs — integrating CMA testing systems

Distributors / channel partners — supplying CMA testing kits

Service providers / after-sales — offering CMA testing services

End users / buyers — undergoing CMA familial testing

Regulators/standards bodies — establishing CMA testing standards

Recent Industry Insights

Analyst Overview

Table of Contents